{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T06:18:15Z","timestamp":1681971495674},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,5,15]]},"DOI":"10.2169\/internalmedicine.1118-18","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:38:01Z","timestamp":1548974281000},"page":"1423-1428","source":"Crossref","is-referenced-by-count":3,"title":["The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site"],"prefix":"10.2169","volume":"58","author":[{"given":"Jun","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"},{"name":"Department of Thoracic Oncology, National Cancer Center Hospital, Japan"},{"name":"Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"},{"name":"Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kodaira","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayu","family":"Yunokawa","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumours. Eur J Cancer 38: 1810-1812, 2002.","DOI":"10.1016\/S0959-8049(02)00135-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39: 1990-2005, 2003.","DOI":"10.1016\/S0959-8049(03)00547-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 69: 271-278, 2009.","DOI":"10.1016\/j.critrevonc.2008.09.005"},{"key":"4","unstructured":"4. National Collaborating Centre for Cancer, National Institute for Health and Clinical Excellence (NICE). Diagnosis and management of metastatic malignant disease of unknown primary origin. National Collaborating Centre for Cancer, Cardiff, United Kingdom, 2010."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13: 2094-2103, 1995.","DOI":"10.1200\/JCO.1995.13.8.2094"},{"key":"6","unstructured":"6. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev 35: 570-573, 2009."},{"key":"7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2407-13-36","volume":"13","author":"M Riihim\u00e4ki","year":"2013","unstructured":"7. Riihim\u00e4ki M, Thomsen H, Hemminki A, Sundquist K, Hemminki K. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer 13: 36, 2013.","journal-title":"BMC Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12885-018-4092-4","volume":"18","author":"M Kodaira","year":"2018","unstructured":"8. Kodaira M, Yonemori K, Shimoi T, et al. Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site. BMC Cancer 18: 176, 2018.","journal-title":"BMC Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"9","unstructured":"9. Fizazi K, Greco FA, Pavlidis N, et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26 (Suppl): v133-v138, 2015."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med 371: 757-765, 2014.","DOI":"10.1056\/NEJMra1303917"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kurahashi I, Fujita Y, Arao T, et al. A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer. PLoS One 8: e63249, 2013.","DOI":"10.1371\/journal.pone.0063249"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 38: 409-413, 2002.","DOI":"10.1016\/S0959-8049(01)00378-1"},{"key":"13","unstructured":"13. Scobie S, Clive S. Vertebral bone biopsy: establishing diagnosis in cancer of unknown primary, National Cancer Research Institute (NCRI) Cancer Conference Abstracts (Abstract #A36). 2015."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Schelfout K, Kersschot E, Van Goethem M, et al. Breast MR imaging in a patient with unilateral axillary lymphadenopathy and unknown primary malignancy. Eur Radiol 13: 2128-2132, 2003.","DOI":"10.1007\/s00330-002-1674-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Olson JA Jr, Morris EA, Van Zee KJ. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 7: 411-415, 2007.","DOI":"10.1007\/s10434-000-0411-4"},{"key":"16","unstructured":"16. Joshi U, van der Hoeven JJM, Comans EFI. In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDG-PET. Br J Radiol 77: 1000-1006, 2004."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101: 2641-2649, 2004.","DOI":"10.1002\/cncr.20687"},{"key":"18","unstructured":"18. Rudmik L, Lau HY, Matthews TW, et al. Clinical utility of PET\/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head Neck 33: 935-940, 2011."},{"key":"19","unstructured":"19. Moller AKH, Loft A, Berthelsen AK, et al. <sup>18<\/sup>F-FDG PET\/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review. Oncologist 16: 445-451, 2011."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Adams HJ, de Klerk JM, Heggelman BG. Malignancy rate of biopsied suspicious bone lesions identified on FDG PET\/CT. Eur J Nucl Med Mol Imaging 43: 1231-1238, 2016.","DOI":"10.1007\/s00259-015-3282-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yabuki K, Tsukuda M, Horiuchi C. Role of <sup>18<\/sup>F-FDG PET in detecting primary site in the patient with primary unknown carcinoma. Eur Arch Otorhinolaryngol 267: 1785-1792, 2010.","DOI":"10.1007\/s00405-010-1371-3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Yu X, Li X, Song X, et al. Advantages and disadvantages of F-18 fluorodeoxyglucose positron emission tomography\/computed tomography in carcinoma of unknown primary. Oncol Lett 12: 3785-3792, 2016.","DOI":"10.3892\/ol.2016.5203"},{"key":"23","unstructured":"23. Elboga U, Kervancio\u011flu S, Sahin E, Basibuyuk M, Celen YZ, Aktolun C. Utility of F-18 fluorodeoxyglucose positron emission tomography\/computed in carcinoma of unknown primary. Int J Clin Exp Pathol 7: 8941-8946, 2014."},{"key":"24","unstructured":"24. Cronin CG, Cashell T, Mhuircheartaigh JN, et al. Bone biopsy of new suspicious bone lesions in patients with primary carcinoma: prevalence and probability of an alternative diagnosis. Am J Roentgenol 193: W407-W410, 2009."},{"key":"25","unstructured":"25. Raphael B, Hwang S, Lefkowitz RA, Landa J, Sohn M, Panicek DM. Biopsy of suspicious bone lesions in patients with a single known malignancy: prevalence of a second malignancy. AJR Am J Roentgenol 201: 1309-1314, 2013."},{"key":"26","unstructured":"26. Ka\u00e7ar \u00d6zkara S, Oz\u00f6ver Tuneli I. Fine needle aspiration cytopathology of liver masses: 101 cases with cyto-\/histopathological analysis. Acta Cytol 57: 332-336, 2013."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kambhu SA, Kelsen DP, Fiore J, et al. Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. Am J Clin Oncol 13: 55-60, 1990.","DOI":"10.1097\/00000421-199002000-00015"},{"key":"28","unstructured":"28. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 10: 912-922, 1992."},{"key":"29","unstructured":"29. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12: 1272-1280, 1994."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. van der, Gaast A, Verweij J, Planting AS, Hop WC, Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 13: 1720-1725, 1995.","DOI":"10.1200\/JCO.1995.13.7.1720"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Seve P, Ray-Coquard I, Trillet-Lenoir V, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 107: 2698-2705, 2006.","DOI":"10.1002\/cncr.22300"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kodaira M, Takahashi S, Yamada S, et al. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Ann Oncol 21: 1163-1167, 2010.","DOI":"10.1093\/annonc\/mdp583"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/10\/58_1118-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T03:37:40Z","timestamp":1558150660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/10\/58_1118-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1118-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]}}}